Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
Thirteen patients with idiopathic myelofibrosis (5 osteomyelosclerosis) were treated with recombinant human erythropoietin (rHuEpo) for transfusion-dependent anemia. All but 7 patients were concomitantly treated with alpha interferon, and 5 patients also received a interferon before the start of erythropoietin (EPO) treatment. All but two patients became transfusion independent. The highly positive results of the present study of transfusion-dependent patients with idiopathic myelofibrosis calls for further studies to delineate more precisely in larger series those patients who are likely to respond to rHuEpo.
Hasselbalch
Hans Carl
HC
Department of Hematology L, Rigshospitalet, Copenhagen, Denmark.
Clausen
Nielsaage Tøffner
NT
Jensen
Bjarne Anker
BA
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001803:Blood Transfusion; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications*; D011994:Recombinant Proteins
D006454:Hemoglobins; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004921:Erythropoietin; D003613:Danazol